University College London and GlaxoSmithKline PLC KTP 24_25 R5

Innovate UK · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$159,325
Est. Value
Closed
Status

Opportunity Overview

To significantly enhance the production of Monoclonal antibodies in a Bioreactor system via the use of Process Analytical Technology, leading to higher quality products and lower costs to patients.

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyInnovate UK
CountryUnited Kingdom
CategoryResearch Development
Estimated value$159,325
PublishedFebruary 01, 2026
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Global Travel, Accommodation and Venue Management Services
NEPRO Total Talent
Capital Programme Delivery Framework(s)
Workforce Solution 2
Technology Products and Associated Services 3
Technology Products and Associated Services 3
GMCA 2201 NW Regional Children’s Services Contract
Integrated Partnerships Framework

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.